IHC and in situ hybridization (ISH) are commonly employed for the evaluation of HER2 overexpression levels in BC, with IHC being widely acknowledged as a cost-effective, time-efficient, and user-friendly method, particularly in resource-limited settings where ISH confirmation may be constrained [7]. This evidence concerns the gene ERBB2 and breast cancer.